Locate Therapeutics secures £2 million to fast-track development of innovative cell therapy programs5 Jun 2018
TAOS matrix system and products hailed as potential ‘game changers’ in the field of regenerative medicine.
Regenerative medicine company, Locate Therapeutics, has closed a £2 million finance package that will help the firm to fast-track its innovative TAOS matrix system and products for spinal fusion and bone regeneration.
The TAOS injectable scaffold matrix system from Locate is a unique regenerative medicine platform that provides an optimal structure to support tissue repair, and can precisely accommodate and promote the actions of regenerative drugs, and emergent cell-based therapies. The injectable particulate formulation of TAOS is thermally-triggered to solidify into a space-filling open porous depot that supports tissue repair before degrading away.
Locate has additional complementary technologies in cell therapy including Intrastem for intracellular delivery of proteins, nucleic acids and particles into cells.
Explaining the implications of this investment, Dr Ian Wilding, Chairman of Locate Therapeutics, said: “We are extremely excited about the potential of our drug delivery technologies to be ‘game changers’ in the field of regenerative medicine, opening up new products to change the lives of patients with severe illnesses. Our company has successfully transitioned from the research to development phase in the last three years and we welcome the backing of Mercia Fund Managers as our investment partner in our journey to commercialisation.
Commenting on the deal completion, Julian Dennard, Investment Director at Mercia, said: “To be able to support innovative firms such as Locate Therapeutics is a key driver for Mercia Fund Managers. This is a great example of how finance available through the MEIF can be leveraged with private money to bring needed capital to a potentially high growth life sciences’ business. We look forward to working with Locate Therapeutics and its partners to drive the business forward, allowing patients to benefit from new treatments by building an exciting next generation drug delivery business.”
Headquartered within MediCity in Nottingham, Locate Therapeutics, a spinout from the University of Nottingham, is leading the way in the development of targeted drug and stem cells delivery systems. This approach enables surgeons to administer stem cells and regenerative drugs to exact locations within the body to maximise efficacy and eliminate safety issues.
Follicum files patent application for new topical formulation for hair loss
30 Apr 2019
Using easy-to-apply cream instead of direct scalp injection would extend patent protection by 8 years.Read more
Hovione Technology acquires global rights to new pulmonary inhaler device
15 Apr 2019
The Papillon DPI is a single-part, blister-based, reusable inhaler, suitable for both chronic and acute treatments.Read more
Isotype-specific secondary antibodies for improved signal detection
10 Apr 2019
Offers an alternative to cross-adsorbed secondary antibodies when absolute specificity is required.Read more
Sterling Pharma to acquire CiVentiChem in the US
9 Apr 2019
The acquisition will enhance the CDMO's chemistry development capabilities to support pre-clinical and early phase clinical supply.Read more
Catalent expands OptiMelt hot melt extrusion capabilities
4 Apr 2019
The investment includes the addition of equipment to enhance development capabilities for preclinical and early clinical phase development, as well as adding downstream processing technologies to support HME formulations.Read more
'Drugs from bugs' joint venture
4 Apr 2019
Lonza and Chr. Hansen create a strategic joint venture to become the partner of choice for developing and manufacturing live biotherapeutic products for pharma and biotech customers.Read more
Curcumin and pomegrantes - new hope for Alzheimer’s prevention?
3 Apr 2019
New research at University of Warwick will test how curcumin kick-starts the brain’s cleansing of damaging plaques and cells.Read more
MedPharm's appointment with Destiny
28 Mar 2019
Global contract provider to develop new XF-platform drug formulations for the treatment of a number of topically treated infections, including diabetic foot ulcers and ophthalmic infections.Read more
Third Sartorius Research Xchange Forum 2019 focuses on CAR-T cell therapy
13 Mar 2019
Event for experts from academia and industry, including talks, live demo sessions, and panel discussion.Read more
Envigo launches PATHWAY to enable FIH clinical trials
11 Mar 2019
PATHWAY manages the complexity of the entire safety assessment process on behalf of the company’s pharmaceutical and biotechnology customers.Read more
Are you a supplier
Here's what we can do for you
- Generate quality leads for your business
- Stay visible for 365 days of the year
- Receive product inquiries and respond to meeting requests directly
- Improve company online presence through Search Engine Optimisation